7-ethyl-10-[4-(1-piperidino)-1-piperidino]carboxyoxycamptothecin methanesulfonic acid salt

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 喜树碱
• 英文名称: 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carboxyoxycamptothecin methanesulfonic acid salt
• 英文别名: [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;methanesulfonic acid
• 化学式: CH₄O₃S*C₃₃H₃₈N₄O₆
• 分子量: 682.795
• InChiKey: QLEZOEQBWPONMI-WAQYZQTGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  48
• 可旋转键数：
  5
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  175
• 氢给体数：
  2
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  甲烷磺酸 、 伊立替康 以 水 为溶剂， 反应 144.0h， 生成 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carboxyoxycamptothecin methanesulfonic acid salt
  参考文献：
  名称：

  EP1798235

  摘要：

  公开号：

文献信息

• ACID ADDITION SALT OF IRINOTECAN
  申请人：KABUSHIKI KAISHA YAKULT HONSHA

  公开号：EP1798235A1

  公开（公告）日：2007-06-20

  The present invention is directed to an irinotecan acid addition salt which is formed through addition of an acid selected from the group consisting of sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, citric acid, maleic acid, and succinic acid to irinotecan, to a method for producing the salt, and to a pharmaceutical composition containing the salt. The addition salt requires no heating process during drug preparation and provides an aqueous drug product in which the salt is stably dissolved.

  本发明涉及一种伊立替康酸加成盐，它是通过将选自硫酸、硝酸、磷酸、甲磺酸、柠檬酸、马来酸和琥珀酸组成的组中的一种酸加成到伊立替康中而形成的，本发明还涉及一种生产该盐的方法，以及一种含有该盐的药物组合物。这种添加盐在药物制备过程中不需要加热过程，并能提供一种盐能稳定溶解的水性药物产品。
• EP1798235B1
  申请人：——

  公开号：EP1798235B1

  公开（公告）日：2015-04-01
• Acid Addition Salt of Irinotecan
  申请人：Shimizu Hideaki

  公开号：US20070299099A1

  公开（公告）日：2007-12-27

  The present invention is directed to an irinotecan acid addition salt which is formed through addition of an acid selected from the group consisting of sulfuric acid, nitric acid phosphoric acid, methanesulfonic acid, citric acid maleic acid and succinic acid to Irinotecan, to a method for producing the salt, and to a pharmaceutical composition containing the salt. The addition salt requires no heating process during drug preparation and provides an aqueous drug product in which the salt is stably dissolved.
• Novel Curcumin-Antibody Conjugates as Anti-Cancer Agents
  申请人：Banerjee Probal

  公开号：US20130224229A1

  公开（公告）日：2013-08-29

  The invention relates to curcumin derivatives having the formula I: wherein: Z represents: H 3 CO A represents —CH 2 —CH 2 — or —CH═CH—; L represents —C(O)—(NH) n1 —R—(NH) n2 —C(O)—; R represents a saturated or unsaturated, branched or unbranched hydrocarbyl chain having a minimum of 3 carbon atoms in the chain; wherein the maximum number of carbon atoms in the chain is 24; and wherein the carbon atoms of the chain can be replaced by at least one heteroatom, wherein the heteroatoms are independently —O— or —NH 2 —, with the proviso that each heteroatom is separated from each other heteroatom by at least two carbon atoms; n1 and n2 independently represent 0 or 1; and Y represents an antibody that binds specifically to a target antigen of a tumor cell. The invention further relates to methods of method of inhibiting the growth of tumors in a human by administering an effective amount of the curcumin derivative, and to methods of producing the curcumin derivative.
• US7897772B2
  申请人：——

  公开号：US7897772B2

  公开（公告）日：2011-03-01